WE ARE BIONEWS SERVICES
BioNews Services is a leading online health, science and research publication company that exists for one purpose: to serve the patient living with a rare disease. We do this by connecting them with current, trusted, relevant news and information. Delivered daily.
AMPLIFYING THE PATIENT VOICE"BioNews patient columnists, like me, are a source of accurate, reliable information about the diseases we live with. Often the news, opinions and experiences that I share will spark on-line conversation. I love making that kind of one-to-one connection."— Ed Tobias, Senior Patient Specialist for Multiple Sclerosis News Today
AMPLIFYING THE PATIENT VOICE"BioNews is providing daily coverage of a wide range of muscular conditions, delivering both research-based content and insightful columns from patient specialists. As a columnist for SMA News Today, I have the opportunity to share my story and educate others about what life with SMA is like."— Kevin Schaefer, Senior Community Outreach Director - SMA and Patient Specialist for SMA News Today
AMPLIFYING THE PATIENT VOICE"As a cystic fibrosis patient, I’ve felt like my disease is more of an identity than a diagnosis. BioNews is a news source that masterfully compiles the research, the patient stories, and the highs and lows of having CF. It portrays the entire picture of what it means to live with this disease."— Reid D’Amico, CF Patient Columnist
SMA Trials to Show if AveXis's Gene Therapy Can Be Game-changer
Read an interview with Sukumar Nagendran, AveXis’s chief medical officer, on clinical trials that could show if its spinal muscular atrophy gene therapy is a game-changer.
For Rare Disease Day, Patient Groups Plan Events Worldwide
Read about the creative and imaginative ways that patient advocacy groups plan to mark Feb. 28, Rare Disease Day, across the U.S. and around the world.
Rare Disease Groups, Patients Differ on 'Right to Try' Bill...
Proposed legislation would open to U.S. patients with life-threatening diseases with few or no approved treatments the ‘Right to Try’ experimental ones outside of the FDA’s oversight. Some favor this, others don’t.
BioNews connects daily and directly with the rare disease patient and caregiver communities that you need to reach. Our multi-channel, multi-content approach fuels these first-in-class services:
LEADING WITH RESULTS
BioNews’ proven ability to build rare disease patient communities who engage with our content daily leads to unparalleled results for our clients: